Sander Bins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sander Bins has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
- Ron H.J. Mathijssen
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
16 shared publications - Stijn L. W. Koolen
Department of Medical Oncology, Erasmus University MC Cancer Institute, Rotterdam, The Netherlands
10 shared publications - Esther Oomen-De Hoop
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Zuid-Holland, The Netherlands
7 shared publications - Mirjam de With
Department of Medical Oncology Erasmus Medical Center Cancer Institute Rotterdam the Netherlands
5 shared publications Ron H. J. Mathijssen
Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands
5 shared publicationsStefan Sleijfer
Dept. of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands; Center for Personalized Cancer Treatment, Rotterdam, the Netherlands
5 shared publications
Latest Publications
- Open Access
- 21 June 2025
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 27, 101063
Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors
- 21 June 2025
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 27, 101063
Open AccessThromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors
- Open Access
- 16 September 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (11) , 1589-1597
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
Background and objective Side effects of irinotecan treatment can be dose limiting and may impair quality of life. In this study, we investigated the correlation between single nucleotide polymorphisms (SNPs) in genes encoding enzymes involved in the irinotecan metabolism and transport, outside UGT1A1, and irinotecan-related toxicity. We focused on carboxylesterases, which are involved in formation of the active metabolite SN-38 and on drug transporters. Methods Patients who provided written informed consent at the Erasmus Medical Center Cancer Institute to the Code Geno study (local protocol: MEC02-1002) or the IRI28-study (NTR-6612) were enrolled in the study and were genotyped for 15 SNPs in the genes CES1, CES2, SLCO1B1, ABCB1, ABCC2, and ABCG2. Results From 299 evaluable patients, 86 patients (28.8%) developed severe irinotecan-related toxicity. A significantly higher risk of toxicity was seen in ABCG2 c.421C>A variant allele carriers (P = 0.030, OR 1.88, 95% CI 1.06–3.34). Higher age was associated with all grade diarrhea (P = 0.041, OR 1.03, 95% CI 1.00–1.06). In addition, CES1 c.1165-41C>T and CES1 n.95346T>C variant allele carriers had a lower risk of all-grade thrombocytopenia (P = 0.024, OR 0.42, 95% CI 0.20–0.90 and P = 0.018, OR 0.23, 95% CI 0.08–0.79, respectively). Conclusion Our study indicates that ABCG2 and CES1 SNPs might be used as predictive markers for irinotecan-induced toxicity.
- 16 September 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (11) , 1589-1597
Open AccessIrinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
Background and objective Side effects of irinotecan treatment can be dose limiting and may impair quality of life. In this study, we investigated the correlation between single nucleotide polymorphisms (SNPs) in genes encoding enzymes involved in the irinotecan metabolism and transport, outside UGT1A1, and irinotecan-related toxicity. We focused on carboxylesterases, which are involved in formation of the active metabolite SN-38 and on drug transporters. Methods Patients who provided written informed consent at the Erasmus Medical Center Cancer Institute to the Code Geno study (local protocol: MEC02-1002) or the IRI28-study (NTR-6612) were enrolled in the study and were genotyped for 15 SNPs in the genes CES1, CES2, SLCO1B1, ABCB1, ABCC2, and ABCG2. Results From 299 evaluable patients, 86 patients (28.8%) developed severe irinotecan-related toxicity. A significantly higher risk of toxicity was seen in ABCG2 c.421C>A variant allele carriers (P = 0.030, OR 1.88, 95% CI 1.06–3.34). Higher age was associated with all grade diarrhea (P = 0.041, OR 1.03, 95% CI 1.00–1.06). In addition, CES1 c.1165-41C>T and CES1 n.95346T>C variant allele carriers had a lower risk of all-grade thrombocytopenia (P = 0.024, OR 0.42, 95% CI 0.20–0.90 and P = 0.018, OR 0.23, 95% CI 0.08–0.79, respectively). Conclusion Our study indicates that ABCG2 and CES1 SNPs might be used as predictive markers for irinotecan-induced toxicity.
- Open Access
- 12 January 2023
- Published by Springer Nature in Drugs
- Vol. 83 (2) , 159-180
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies
Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier. Intraperitoneal chemotherapy, which is administered repeatedly into the peritoneal cavity through a peritoneal implanted port, could provide a novel treatment modality for this patient population. This review provides a systematic overview of intraperitoneal used drugs, the performed clinical studies so far, and the complications of the peritoneal implemental ports. Several anticancer drugs have been studied for intraperitoneal application, with the taxanes paclitaxel and docetaxel as the most commonly used drug. Repeated intraperitoneal chemotherapy, mostly in combination with systemic chemotherapy, has shown promising results in Phase I and Phase II studies for several tumor types, such as gastric cancer, ovarian cancer, colorectal cancer, and pancreatic cancer. Two Phase III studies for intraperitoneal chemotherapy in gastric cancer have been performed so far, but the results regarding the superiority over standard systemic chemotherapy alone, are contradictory. Pressurized intraperitoneal administration, known as PIPAC, is an alternative way of administering intraperitoneal chemotherapy, and the first prospective studies have shown a tolerable safety profile. Although intraperitoneal chemotherapy might be a standard treatment option for patients with unresectable peritoneal disease, more Phase II and Phase III studies focusing on tolerability profiles, survival rates, and quality of life are warranted in order to establish optimal treatment schedules and to establish a potential role for intraperitoneal chemotherapy in the approach to unresectable peritoneal disease.
- 12 January 2023
- Published by Springer Nature in Drugs
- Vol. 83 (2) , 159-180
Open AccessIntraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies
Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier. Intraperitoneal chemotherapy, which is administered repeatedly into the peritoneal cavity through a peritoneal implanted port, could provide a novel treatment modality for this patient population. This review provides a systematic overview of intraperitoneal used drugs, the performed clinical studies so far, and the complications of the peritoneal implemental ports. Several anticancer drugs have been studied for intraperitoneal application, with the taxanes paclitaxel and docetaxel as the most commonly used drug. Repeated intraperitoneal chemotherapy, mostly in combination with systemic chemotherapy, has shown promising results in Phase I and Phase II studies for several tumor types, such as gastric cancer, ovarian cancer, colorectal cancer, and pancreatic cancer. Two Phase III studies for intraperitoneal chemotherapy in gastric cancer have been performed so far, but the results regarding the superiority over standard systemic chemotherapy alone, are contradictory. Pressurized intraperitoneal administration, known as PIPAC, is an alternative way of administering intraperitoneal chemotherapy, and the first prospective studies have shown a tolerable safety profile. Although intraperitoneal chemotherapy might be a standard treatment option for patients with unresectable peritoneal disease, more Phase II and Phase III studies focusing on tolerability profiles, survival rates, and quality of life are warranted in order to establish optimal treatment schedules and to establish a potential role for intraperitoneal chemotherapy in the approach to unresectable peritoneal disease.
- Open Access
- 9 January 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 159, 114232
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD
- 9 January 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 159, 114232
Open AccessCapecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD
- Open Access
- 6 January 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 159, 114210
Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors
- 6 January 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 159, 114210
Open AccessIdentifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors
- 10 November 2022
- Published by Springer Nature in British Journal of Cancer
- Vol. 128 (2) , 354-362
Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension
Background Vascular endothelial growth factor inhibitors (VEGFIs) are effective anticancer agents which often induce hypertension. VEGFI-induced hypertension is sodium-sensitive in animal studies. Therefore, the efficacy of dietary sodium restriction (DSR) to prevent VEGFI-induced hypertension in cancer patients was studied. Methods Cancer patients with VEGFI-induced hypertension (day mean >135/85 mmHg or a rise in systolic and/or diastolic BP ≥ 20 mmHg) were treated with DSR (aiming at P = 0.009). DSR prevented the rise in the endothelin-1/renin ratio that normally accompanies VEGFI-induced hypertension (P = 0.020) and prevented the onset of proteinuria: 0.15 (0.10–0.25) g/24 h with DSR versus 0.19 (0.11–0.32) g/24 h without DSR; P = 0.005. Discussion DSR significantly attenuated VEGFI induced BP rise and proteinuria and thus is an effective non-pharmacological intervention.
- 10 November 2022
- Published by Springer Nature in British Journal of Cancer
- Vol. 128 (2) , 354-362
Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension
Background Vascular endothelial growth factor inhibitors (VEGFIs) are effective anticancer agents which often induce hypertension. VEGFI-induced hypertension is sodium-sensitive in animal studies. Therefore, the efficacy of dietary sodium restriction (DSR) to prevent VEGFI-induced hypertension in cancer patients was studied. Methods Cancer patients with VEGFI-induced hypertension (day mean >135/85 mmHg or a rise in systolic and/or diastolic BP ≥ 20 mmHg) were treated with DSR (aiming at P = 0.009). DSR prevented the rise in the endothelin-1/renin ratio that normally accompanies VEGFI-induced hypertension (P = 0.020) and prevented the onset of proteinuria: 0.15 (0.10–0.25) g/24 h with DSR versus 0.19 (0.11–0.32) g/24 h without DSR; P = 0.005. Discussion DSR significantly attenuated VEGFI induced BP rise and proteinuria and thus is an effective non-pharmacological intervention.
- Open Access
- 18 August 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 174, 113-120
Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
- 18 August 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 174, 113-120
Open AccessAssociations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study
- 1 July 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2200180
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events
PURPOSE: Around 20%-30% of patients treated with fluoropyrimidines develop severe treatment-related adverse events (AEs). These are mainly caused by deficiency of dihydropyrimidine dehydrogenase, its main metabolizing enzyme. The DPYD*7 variant allele contains a frameshift mutation that leads to absence of dihydropyrimidine dehydrogenase. Clinical studies on this variant in patients treated with fluoropyrimidines are lacking because of its low minor allelic frequency. However, the DPYD*7 minor allelic frequency is 56-times higher in the Dutch compared with the global population. This allowed us to evaluate fluoropyrimidine tolerability in DPYD*7 variant allele carriers. MATERIALS AND METHODS: Patients treated with standard-of-care fluoropyrimidine who were pretreatment DPYD genotyped for DPYD*2A, *13, 2846A>T, and 1236G>A single-nucleotide polymorphisms were included for analyses. Patients were additionally screened for the DPYD*7 allele (rs72549309, 295-298delTCAT). AEs were graded if they worsened from baseline, according to Common Terminology Criteria for Adverse Events version 5.0. AEs ≥ grade 3 were considered severe. RESULTS: From 3,748 patients, we found 13 patients carrying heterozygous DPYD*7. Relevant clinical data were available for 11 patients. All patients developed fluoropyrimidine-related AEs, of which five patients developed severe AEs (46%). From these five patients, three patients were started with 65% or 50% of standard dose, but apparently still developed severe toxicity. Because of severe AEs, three patients discontinued treatment prematurely (one patient already started with 50% of standard dose) and one patient who started with 50% of standard dose was further reduced to 35% of standard dose. CONCLUSION: In this study, the clinical consequences of carrying the DPYD*7 variant allele were confirmed as 46% of the patients developed severe AEs, even in the presence of initial dose reductions. This underlines the need for prospective studies investigating the required fluoropyrimidine dose for DPYD*7 carriers.
- 1 July 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2200180
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events
PURPOSE: Around 20%-30% of patients treated with fluoropyrimidines develop severe treatment-related adverse events (AEs). These are mainly caused by deficiency of dihydropyrimidine dehydrogenase, its main metabolizing enzyme. The DPYD*7 variant allele contains a frameshift mutation that leads to absence of dihydropyrimidine dehydrogenase. Clinical studies on this variant in patients treated with fluoropyrimidines are lacking because of its low minor allelic frequency. However, the DPYD*7 minor allelic frequency is 56-times higher in the Dutch compared with the global population. This allowed us to evaluate fluoropyrimidine tolerability in DPYD*7 variant allele carriers. MATERIALS AND METHODS: Patients treated with standard-of-care fluoropyrimidine who were pretreatment DPYD genotyped for DPYD*2A, *13, 2846A>T, and 1236G>A single-nucleotide polymorphisms were included for analyses. Patients were additionally screened for the DPYD*7 allele (rs72549309, 295-298delTCAT). AEs were graded if they worsened from baseline, according to Common Terminology Criteria for Adverse Events version 5.0. AEs ≥ grade 3 were considered severe. RESULTS: From 3,748 patients, we found 13 patients carrying heterozygous DPYD*7. Relevant clinical data were available for 11 patients. All patients developed fluoropyrimidine-related AEs, of which five patients developed severe AEs (46%). From these five patients, three patients were started with 65% or 50% of standard dose, but apparently still developed severe toxicity. Because of severe AEs, three patients discontinued treatment prematurely (one patient already started with 50% of standard dose) and one patient who started with 50% of standard dose was further reduced to 35% of standard dose. CONCLUSION: In this study, the clinical consequences of carrying the DPYD*7 variant allele were confirmed as 46% of the patients developed severe AEs, even in the presence of initial dose reductions. This underlines the need for prospective studies investigating the required fluoropyrimidine dose for DPYD*7 carriers.
- 21 April 2022
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 112 (1) , 24
Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported
- 21 April 2022
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 112 (1) , 24
Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported
- Open Access
- 5 January 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 162, 148-157
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients
- 5 January 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 162, 148-157
Open AccessUGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients